🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

The Zacks Analyst Blog Highlights: Dow Chemical, Celgene, Ford, BB&T And Sony

Published 11/03/2016, 12:01 AM
Updated 07/09/2023, 06:31 AM
US500
-
DJI
-
DOW
-
CELG
-
TFC
-
DD
-

For Immediate Release

Chicago, IL – November 03, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Dow Chemical (NYSE:DOW) (NYSE:DOW-Free Report), Celgene (NASDAQ:CELG) (NASDAQ:CELG-Free Report), Ford (NYSE:F-Free Report), BB&T Corp (NYSE:BBT) (NYSE:BBT-Free Report) and Sony (NYSE:SNE- Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Top Research Reports for Today

Today's Research Daily features new research reports on 16 major stocks, including Dow Chemical (NYSE:DOW-Free Report), Celgene (NASDAQ:CELG-Free Report), and Ford (NYSE:F- Free Report).

Dow Chemical shares have lagged the basic materials sector this year, but have performed largely in-line with the S&P 500 index. The company's third-quarter results exceeded expectations, aided by its productivity and cost-reduction actions. The analyst likes Dow’s productivity and aggressive portfolio management actions as well as strategic investments in the U.S. Gulf Coast and the Middle East. The company is also moving forward with its planned mega-merger with DuPont (NYSE:DD), which is expected to create significant synergies. Dow should also gain from cost synergies associated with Dow Corning Silicones business in 2016. (You can read the full research report on Dow Chemical here>>)

Buy rated Celgene shares have been laggards this year, as have been other drug makers given ongoing questions about pricing issues and other regulatory uncertainties. These issues notwithstanding, Celgene’s third-quarter results were better than expected with the company beating on both top- and bottom-line estimates. Multiple myeloma drug Revlimid continued to grow on the back of market share gains and increased duration. The analyst likes Celgene’s ongoing label expansion efforts and pipeline development. The company anticipates several pipeline-related events over the upcoming quarters and next few years. Celgene’s raised and updated its expectations for both 2016 and 2017, are also encouraging. (You can read the full research report on Celgene here>>)

Ford 's Q3 results came in better than expected, but expectations were low given management's negative guidance following the June quarter report. The stock stands out for its underperformance - it has lagged GM, the broader auto space as well as the S&P 500 (down more than 17% year to date). The automaker's full-year 2016 pre-tax profit, adjusted earnings per share and automotive operating margin to be lower than 2015. Further, results from most regions are expected to be weaker this year. In the updated research report issued today, the analyst discusses the pros & cons of investing in Ford shares at present. Of the positives in the Ford story, the analyst points out Ford’s product launches, global expansion plans, efficient capital deployment, success of the One Ford plan, focus on autonomous vehicle development and solid long-term outlook. But Ford expects 2016 (You can read the full research report on Ford here>>)

Other noteworthy reports we are featuring today include BB&T Corp (NYSE:BBT-Free Report) and Sony (NYSE:SNE- Free Report).

Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on DOW - FREE

Get the full Report on CELG - FREE

Get the full Report on F - FREE

Get the full Report on BBT - FREE

Get the full Report on SNE - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.



DOW CHEMICAL (DOW): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

FORD MOTOR CO (F): Free Stock Analysis Report

BB&T CORP (BBT): Free Stock Analysis Report

SONY CORP ADR (SNE): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.